Participant in KPWHRI trial receives world’s first-ever injection of investigational SchistoShield vaccination.
NIAID-sponsored study includes Seattle in test for benefits of mixing different vaccine types.
An investigational vaccine developed by Moderna is being tested for safety and immune response in Seattle and 3 other cities.
Lisa Jackson, MD, MPH, Kaiser Permanente Washington senior investigator, recounts the genesis of a groundbreaking vaccine.
A registry started by KPWHRI last year has sped up studies needed to protect the world against the novel coronavirus.
Now more than ever we can benefit from studies embedded in health-care systems to answer common clinical questions.
Lisa A. Jackson, MD, MPH, is leading a study of pneumococcal vaccine in older adults at six Vaccine and Treatment Evaluation Units (VTEUs) across the nation, including at Group Health. Dr. Jackson, a senior investigator at Group Health Research Institute, leads the Seattle-area VTEU. Dr. Jackson and her colleagues plan to see if a higher dose of a pneumococcal vaccine will create a stronger immune response in older adults who received an earlier-generation vaccine against pneumonia and other pneumococcal diseases.
Our Seattle offices sit on the occupied land of the Duwamish and by the shared waters of the Coast Salish people, who have been here thousands of years and remain. Learn about practicing land acknowledgment.